VirRx, Inc. (VirRx) is a biotechnology company that focuses on cancer gene therapy. The research team of the company has an extensive knowledge on human adenoviruses, including construction of human adenovirus vectors for cancer gene therapy. It is also lays emphasis on developing novel drugs to treat various kinds of human cancer. The company has developed a cancer gene therapy vector which destroys only the affected tissue unlike other therapies. Further, the company will begin Phase I trials on vectors for the treatment of human cancer. VirRx is headquartered at St. Louis, in Missouri, the US.